SCHEMBL4898620

SCHEMBL4898620

CCOC(=O)c1ccc(Nc2nc(Nc3ccc(C(=O)OCC)cc3)c3nc[nH]c3n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 1/20 0.61
KMT2A Q03164 7/20 0.59
RAB9A P51151 6/20 0.59
MEN1 O00255 5/20 0.59
THRB P10828 1/20 0.59
KDM4E B2RXH2 7/20 0.58
HPGD P15428 5/20 0.58
NPC1 O15118 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
HSD17B10 Q99714 3/20 0.58
TP53 P04637 2/20 0.58
PDPK1 O15530 1/20 0.55
SLC2A1 P11166 1/20 0.50
ALDH1A1 P00352 7/20 0.48
MAPT P10636 3/20 0.48
EGFR P00533 1/20 0.48
KDR P35968 1/20 0.48
CYP1A2 P05177 1/20 0.48
POLB P06746 1/20 0.48
CYP3A4 P08684 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7107687 0.96 ALK (0.57) ALKKMT2ARAB9AMEN1THRB
SCHEMBL4892691 0.93 ALK (0.55) ALKKMT2ARAB9AMEN1THRB
SCHEMBL4893816 0.92 SMN1; SMN2 (0.59) ALKKMT2ARAB9AMEN1THRB
SCHEMBL4894962 0.90 BRAF (0.54) ALKKMT2ARAB9AMEN1THRB
SCHEMBL7104854 0.87 SMN1; SMN2 (0.56) ALKKMT2ARAB9AMEN1THRB
SCHEMBL4892709 0.87 RAB9A (0.50) ALKKMT2ARAB9AMEN1THRB
SCHEMBL4901287 0.86 RAB9A (0.50) ALKKMT2ARAB9AMEN1THRB
SCHEMBL4891943 0.86 RAB9A (0.49) ALKKMT2ARAB9AMEN1THRB
SCHEMBL12253193 0.80 MEN1 (0.83) ALKKMT2ARAB9AMEN1THRB
SCHEMBL7110003 0.79 NPY5R (0.48) RAB9ANPC1SLC2A1MAPTEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041824-B2 Purine derivatives, preparation method and use as medicines AVENTIS PHARMA S.A. (FR) 2006-05-09 US claimed
US-20040063732-A1 Novel purine derivatives, preparation method and use as medicines AVENTIS PHARMA S.A. (FR) 2004-04-01 US claimed
US-20080090849-A1 NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES AVENTIS PHARMA S.A. (FR) 2008-04-17 US disclosed
US-7041824-B2 Purine derivatives, preparation method and use as medicines AVENTIS PHARMA S.A. (FR) 2006-05-09 US disclosed
US-20060074095-A1 Novel purine derivatives, preparation method and use as medicines AVENTIS PHARMA S.A. (FR) 2006-04-06 US disclosed
US-20040063732-A1 Novel purine derivatives, preparation method and use as medicines AVENTIS PHARMA S.A. (FR) 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063732-A1 Novel purine derivatives, preparation method and use as medicines CDK1, CDK6, PNP ALK 2746/4885KMT2A 1869/4885RAB9A 3267/4885
US-20080090849-A1 NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES CDK1, CDK6, PNP ALK 1968/4885KMT2A 1456/4885RAB9A 3073/4885
US-20060074095-A1 Novel purine derivatives, preparation method and use as medicines CDK1, CDK6, PNP ALK 2380/4885KMT2A 1673/4885RAB9A 3104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.